Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT relapse prevention maintenance trial in schizophrenia
2025-523664-20-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing KarXT continuation with Placebo withdrawal (2 arms). Primary endpoints: Time to relapse, Symptom worsening on PANSS or CGI-S and 4 more. Planned start Oct 2026; status: authorised.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2025-523664-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523664-20-00.